Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Analyst Coverage
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

SEC Filings

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
Mar 20, 2023 SC 13G

A statement of beneficial ownership of common stock by certain persons

Other
View HTML
0001140361-23-012589.pdf
0001140361-23-012589.rtf
0001140361-23-012589.xls
Mar 10, 2023 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0000950170-23-007135.pdf
0000950170-23-007135.rtf
0000950170-23-007135.xls
Mar 06, 2023 SC 13G

A statement of beneficial ownership of common stock by certain persons

Other
View HTML
0000921895-23-000654.pdf
0000921895-23-000654.rtf
0000921895-23-000654.xls
Mar 03, 2023 F-6 POS

Post-effective amendment to a previously filed F-6

Registration Statements
View HTML
0001193805-23-000272.pdf
0001193805-23-000272.rtf
0001193805-23-000272.xls
Feb 24, 2023 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-23-047981.pdf
0001193125-23-047981.rtf
0001193125-23-047981.xls
Feb 14, 2023 SC 13G/A

An amendment to the SC 13G filing

Other
View HTML
0000902664-23-001739.pdf
0000902664-23-001739.rtf
0000902664-23-001739.xls
Feb 14, 2023 SC 13G/A

An amendment to the SC 13G filing

Other
View HTML
0001214659-23-002391.pdf
0001214659-23-002391.rtf
0001214659-23-002391.xls
Jan 31, 2023 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0000950170-23-001415.pdf
0000950170-23-001415.rtf
0000950170-23-001415.xls
Jan 04, 2023 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0000950170-23-000085.pdf
0000950170-23-000085.rtf
0000950170-23-000085.xls
Dec 21, 2022 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0000950170-22-026849.pdf
0000950170-22-026849.rtf
0000950170-22-026849.xls

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com